Perfexion Brain Metastasis (HFA-SRT)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Brain metastases occur in 20% to 40% of all patients with cancer , with an incidence 10 times higher than that of primary malignant brain tumors. Patients with brain metastases have a poor prognosis with a median survival of 1-2 months with corticosteroids and 5-7 months with whole brain radiotherapy (WBRT). Local control achieved with WBRT in patients with otherwise controlled systemic disease remains at issue. A single high dose of radiation delivered with high precision to the target lesion (Stereotactic radiosurgery (SRS)), is considered standard care in salvage of recurrent lesions after WBRT. SRS can destroy tumour with very little damage to surrounding tissue. Research suggests that delivering radiotherapy in a number of smaller doses is more beneficial than receiving all of the radiotherapy in a single dose. Brain metastases are well suited for SRS as they are often small, radiographically well-circumscribed, pseudospherical tumors that are noninfiltrative.
| Condition | Intervention | Phase |
|---|---|---|
|
Brain Metastases |
Radiation: Hypofractionated stereotactic radiotherapy |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Hypofractionated and Adaptive Stereotactic Radiotherapy (HFA-SRT) for Large-Volume Brain Metastases |
- This study aims to determine what the maximum tolerated dose of hypofractionated adaptive stereotactic radiotherapy (HFA-SRT) for recurrent brain metastases is. [ Time Frame: every 3 months for 3 years ] [ Designated as safety issue: Yes ]
- The secondary outcome will be to evaluate the overall survival and change in tumour response. [ Time Frame: every 3 months for 3 years ] [ Designated as safety issue: Yes ]
- Measure acute and late toxicities [ Time Frame: every 3 months for 3 years ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 48 |
| Study Start Date: | December 2008 |
| Estimated Study Completion Date: | November 2015 |
| Estimated Primary Completion Date: | November 2015 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: (HFA-SRT) in Large-Volume Brain Metastases |
Radiation: Hypofractionated stereotactic radiotherapy
Patients will be initially administered 8 Gy RT (level). The dose at each level will be increase by 2 Gy up to level 4. If ≥ 2 of the patients in a dose cohort encounter a DLT, then that dose level will be declared the maximum administered dose. An additional 3 patients will then be entered at the previous dose level and provided no more than one patient experiences a DLT, that level will be declared the maximum tolerated dose (MTD). Up to 6 more patients can be treated at the given dose level while awaiting the results of 6 months of follow-up.
|
Detailed Description:
With increasing volume of tumor, the dose of radiosurgery that can be safely delivered to recurrent oligo-metastases in the brain must be reduced. However, reducing the dose of radiosurgery also compromises local control. There is mounting evidence of a local control benefit to a hypofractionated approach in radiation delivery for brain metastases compared with single fraction radiosurgery. Here we propose a novel therapeutic strategy that builds on this concept whereby time between each delivered fraction will enable us to measure and adapt to response, with the objective of reducing irradiated volumes and improving outcomes. In general, the treatment of malignant tumors benefits from fractionation of the dose due to a number of radiobiological properties (redistribution, reoxygenation, repair) that distinguish, and select against, malignant lesions in the fractionation process. Hypofractionated stereotactic radiotherapy (HSRT) is a method of delivering a highly conformal dose distribution in a few treatment sessions using a relocatable stereotactic frame. HSRT may be an attractive alternative to SRS because it may 1) improve patient comfort by removing the invasive nature of SRS frames, 2) confer a radiobiologic advantage over single fraction treatment.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- 1-5 recurrent brain metastases after WBRT, and
- At least 1 lesions >2cm in maximum diameter
- ECOG 0-2
- Life expectancy >3months
- Age ≥ 18 years old
Exclusion Criteria:
- Edentulous patients
- Prior surgery or injury to hard palate
- Severe claustrophobia
- Contraindication to MRI
- Contraindication to IV contrast (Gadolinium) administration
- Other medical conditions that would preclude study investigations
- Prior radiosurgery to recurrent lesions
- Radiation cannot be delivered at the assigned dose level in a manner that respects OAR constraints (3.2.2.4.2.3.4) (e.g. lesions within brainstem or abutting optic structures)
- Any lesion >5cm in diameter, or total volume of tumor > 60cc
Contacts and Locations| Contact: Cynthia Ménard, MD | 416 946 4501 ext 6513 | cynthia.menard@rmp.uhn.on.ca |
| Canada, Ontario | |
| University Health Network | Recruiting |
| Toronto, Ontario, Canada, M5G 2M9 | |
| Contact: Cynthia Ménard, MD 416-946-4501 ext 6513 cynthia.menard@rmp.uhn.on.ca | |
| Principal Investigator: Cynthia Ménard, MD | |
| Principal Investigator: | Cynthia Ménard, MD | University Health Network, Princess Margaret Hospital |
More Information
No publications provided
| Responsible Party: | University Health Network, Toronto |
| ClinicalTrials.gov Identifier: | NCT00805103 History of Changes |
| Other Study ID Numbers: | UHN REB 08-0602-C |
| Study First Received: | December 8, 2008 |
| Last Updated: | January 3, 2013 |
| Health Authority: | Canada: Ethics Review Committee |
Keywords provided by University Health Network, Toronto:
|
Brain Metastases Stereotactic radiosurgery (SRS) Hypofractionated stereotactic radiotherapy (HSRT) Recurrent Brain Metastases |
Additional relevant MeSH terms:
|
Neoplasm Metastasis Neoplasms, Second Primary Brain Neoplasms Neoplastic Processes Neoplasms Pathologic Processes |
Central Nervous System Neoplasms Nervous System Neoplasms Neoplasms by Site Brain Diseases Central Nervous System Diseases Nervous System Diseases |
ClinicalTrials.gov processed this record on May 19, 2013